cyrilzakka/clinical-trials huggingface dataset:
Effects of RAS in Stroke

The goal of this study is to to examine whether rhythmic auditory stimulation improved movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients. The main questions it aims to answer are:

* Does rhythmic auditory stimulation improve movement speed in stroke patients?
* Does rhythmic auditory stimulation improve movement function of executing activities of daily living in stroke patients?
* Does rhythmic auditory stimulation improve movement recovery of the affected upper limb in stroke patients?
* Does rhythmic auditory stimulation improve quality of life in stroke patients?

Researchers will compare movement training with the aid of rhythmic auditory stimulation to movement training without the aid of rhythmic auditory stimulation to see if rhythmic auditory stimulation works to improve movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients.

Participants will:

* Undergo movement tests and fill out questionnaires before and after the movement training program
* Receive movement training for 40 minutes per session and three sessions per week for a total of 24 sessions


Eligibility Criteria:
Inclusion Criteria:

* (1) Diagnosed with either ischaemic or hemorrhagic stroke, and a first-time occurrence;
* (2) A unilateral stroke;
* (3) The onset occurred six months or more prior to the experiment, indicating a chronic stage of stroke;
* (4) The affected upper limb's proximal and distal joints are between Brunnstrom stages four to six, ensuring that the affected limb can execute the upper-limb functional movement training of this study;
* (5) The affected upper limb's Modified Ashworth Scale score is ≤ 2, indicating no significant muscle stiffness (spasticity) in the affected limb;
* (6) A Montreal Cognitive Assessment score of ≥ 24, ensuring comprehension of the instructions given during this study;
* and (7) when we clap hands next to the affected ear of the participant who closes eyes, the participant is able to indicate the sound's source either verbally or through gestures, indicating no complete hearing loss in the affected ear and the ability to receive rhythmic auditory stimulation.

Exclusion Criteria:

* (1) Neurological diseases or medical conditions that affect upper-limb movements or hearing;
* (2) Being participating in other experimental studies related to drug treatment or upper-limb movement therapy.
Evaluation of a Computer-Delivered 5 A's Intervention for Smoking

This is a 2-group RCT in 380 tobacco-using medical patients that will compare a single session, computer-directed 5 A's intervention for smoking (experimental condition) to screening and resource provision (control condition). Follow-up visits will occur at 1 and 3 months post study enrollment. Measures will focus on tobacco use and related psychosocial outcomes (e.g. mood, stress). We will compare resources used and economic costs needed to implement each intervention.

The Investigators hypothesize that patients receiving the computer-directed intervention will have significantly higher tobacco abstinence rates at 3 months post study enrollment compared to the control group. If indeed the computerized intervention increases tobacco abstinence rates compared to the control group, this intervention could be used to increase access to treatment for the millions of US smokers, ultimately reducing tobacco mortality and morbidity rates in this country.


Eligibility Criteria:
Inclusion Criteria:

* 18 - 65 years
* Primary care patient
* Smoked at least one cigarette per day for the past seven days or at least 10 cigarettes total during the past week
* Smoked at least 100 cigarettes (lifetime)
* Had no recent (past 90 days) use of other forms of tobacco (pipes, cigars, NRT)
* Able to speak English

Exclusion Criteria:

- Pregnant
Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix

To evaluate the value of vaginal progesterone therapy for reduction of preterm labor in asymptomatic twin pregnancies who have sonographic short cervix

Women with twin pregnancy with transvaginal sonographic cervical length of 20-25 mm at 20-24 weeks gestational age without symptoms, signs or other risk factors of preterm labor will be included in the study. All women will be randomly divided into two groups; one group (study group) received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 20-24 weeks gestational age (study group) and the other group received no treatment (control group)

Eligibility Criteria:
Inclusion Criteria:

* Women pregnant in dichorionic twins.
* Transvaginal sonographic cervical length is 20-25 mm at 20-24 weeks gestational age.
* No symptoms, signs or other risk factors for preterm labor.

Exclusion Criteria:

* Age \< 20 years or \> 35 years.
* Known allergy or contraindication (relative or absolute) to progesterone therapy.
* Pregnancy by in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI).
* Monochorionic twins.
* Known major fetal structural or chromosomal abnormality.
* Intrauterine death of one fetus or death of both fetuses.
* Fetal reduction in current pregnancy.
* Cervical cerclage in current pregnancy.
* Medical conditions that may lead to preterm delivery.
* Rupture of membranes.
* Vaginal bleeding.
Early Cognitive Intervention in Delirium

This is a randomized control trial to determine if early cognitive training and rehabilitation improve 4-month cognition in hospitalized older (\>=65 years old) delirious patients with and without Alzheimer's disease and related dementias. Enrolled patients will be randomized to receive cognitive intervention versus usual care at a 1:2 allocation ratio. Patients assigned to the cognitive intervention group will receive cognitive training daily during hospitalization and cognitive rehabilitation weekly for 12 weeks after hospital discharge. Patients will be evaluated for global cognition (primary outcome) and secondary outcomes at 4-months.


Eligibility Criteria:
Inclusion Criteria:

* 65 years or older
* Admitted through the ED
* Cognitive training can be initiated within 24 hours of ED presentation
* Delirious at enrollment

Exclusion Criteria:

* Comatose
* Not able to follow simple commands or non-verbal prior to the acute illness (end-stage pre-illness ADRD)
* Resides in a nursing home
* Prisoner
* Receiving hospice care
* Lives \> 100 miles away from the enrolling sites
* Non-English speaking
* Previously enrolled
* Deaf or blind
* Intravenous drug, crack or cocaine, or methamphetamine use within the past one year, or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
* Psychotic disorder or suicidal gesture requiring hospitalization with the past one year
* Discharged from the ED
Online Exercise Intervention for Psychosis Patients Receiving Residential Care

The main objective of this randomised controlled trial (RCT) is to investigate the immediate and long-term effectiveness of 8-week online exercise intervention for people with psychosis receiving residential care.

The effect will also be evaluated after 6-month and 12-month, anticipate seeing the maintenance of physical activity throughout a year of time.

The secondary objective of this RCT is to investigate if the exercise intervention will be effective in improving the clinical symptoms, cognitive functioning and social functioning of the subjects, and to see if the improvement can be maintained (or improve) over a longer period of time (i.e., 6-month and 12-month).

Eligibility Criteria:
Inclusion Criteria:

* Based on the Fifth version of the Diagnostic and Statistical Manual of Mental Disorders diagnosis to have schizophrenia and related psychotic disorders
* Have the ability to understand Chinese
* Able to give informed consent

Exclusion Criteria:

* Severe physical illness (Myocardial Infarction, Hypertension, Fracture, Spinal problems in which exercise may be contraindicated), and seizure disorders.
* Comorbid substance dependence
* Unstable psychotic symptoms
* Any history of brain trauma or organic brain disease
* Known history of intellectual disability or special school attendance
* Other mental conditions that requires other treatment priorities, e.g., suicidal risk.
* Other medical conditions that severely limits participation, comprehension, or adherence to the treatment or assessment e.g., epilepsy, dementia, terminal medical illness.
Efficacy of Music Therapy Protocols for Burn Debridement

The purpose of this prospective, crossover randomized study is to explore the efficacy of two music therapy protocols on pain, anxiety, and muscle tension levels throughout the debridement process in individuals hospitalized with moderate to severe burns.

The study is a prospective, randomized crossover clinical trial conducted on a 14-bed inpatient comprehensive burn care center. The purpose of this study is to investigate the efficacy of Music-Based Imagery (MBI) and Music Alternate Engagement (MAE) for pain and anxiety management for burn patients throughout the debridement process.

Eligibility Criteria:
Inclusion Criteria:

* Patient is admitted for at least three days (excluding day of admission)
* Patient is at least seven years old
* Patient is able to communicate, i.e. awake and alert
* Patient is oriented

Exclusion Criteria:

* Patient admitted for/less than three days
* Patient under seven years of age
* Patient not able to communicate, i.e. sedated and/or intubated
* Patient is not oriented, i.e. active psychosis, hallucinations, delusions, late-stage Alzheimer's or dementia diagnoses
Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers

Lutein is one of oxygenated carotenoids. Over the past few years, there has been increased interest in evaluating the effect of lutein for optimizing immune functions. A large number of epidemiological studies support the notion that a high intake of lutein is associated with a reduced risk of coronary heart disease and certain types of cancer. The biological mechanisms for the protective effects of this carotenoid, including powerful modulation of functions and antioxidant properties, are only partially known. Although several nutrients and phytochemicals have been shown to modulate immune functions in humans, few studies have investigated the role of lutein consumption. No information is available as to whether lutein supplementation could be protective against oxidative stress. Therefore, the objective of the present study was to examine the effect of consuming different doses of lutein on oxidative stress in healthy subjects.

Participants with a history of smoking, alcohol consumption, body mass index (BMI)≥30kg/m2, allergies, ocular diseases and participants taking vitamins or other food supplements containing lutein were excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adult subjects aged in the range of 20 to 80

Exclusion Criteria:

* Participants with a history of smoking
* Alcohol consumption
* Body mass index (BMI)≥30kg/m2
* Allergies
* Ocular diseases or recent infections(within the last year) and participants taking vitamins or other food supplements containing lutein the previous 2 months.
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis

The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery disease on Cardiac Computed Tomography Angiography (CCTA).

Patients underwent a cardiac MRI examination with Dotarem within 60 days after screening visit. The myocardial CCTA examination with Xenetix 350 was performed within 1 to 30 days (but no sooner than 24 hours) after the MRI examination.

Eligibility Criteria:
Inclusion Criteria:

* Patient with onset of type 2 diabetes occurred at age 30 years or older
* Patient between the ages of 50 and 75 years at enrolment time
* Patient with at least two identified cardiac risk factors who will undergo a CMR and a CCTA examinations to evaluate his/her coronary and cardiac status

Exclusion Criteria:

* Patient with angina pectoris or chest discomfort
* Patient with stress test or invasive coronary angiography within the prior 3 years
* Patient with history of myocardial infarction, overt non compensated heart failure, or coronary revascularization
* Patient with hemodynamic instability.
* Patient with a contraindication or intolerance to Beta-Blocker administration
Prevention of Severe Postpartum Hypertension

The purpose of this study is to determine whether postpartum administration of furosemide to women with antepartum hypertensive disorders (gestational hypertension, preeclampsia) or elevated blood pressure in the first 24 hours following delivery reduces severe postpartum hypertension.


Eligibility Criteria:
Inclusion Criteria:

Women \> 18 years of age or emancipated minors

Women undergoing vaginal or cesarean delivery at \> 23 weeks gestation with:

* Antepartum diagnosis of gestational hypertension
* Antepartum diagnosis of preeclampsia
* Antepartum diagnosis of preeclampsia with severe features
* Mild hypertension (\<150/100) in first 24 hours following delivery

Exclusion Criteria:

* Chronic hypertension
* Allergy to furosemide
* Pre-existing hypokalemia (serum K \< 3.0 meq/L)
* Chronic kidney disease
* Serum Cr \> 1.1
* Inability to obtain informed consent
* Pre-existing diuretic use
* Oliguria
Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis

This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.

The primary objective of the study is to evaluate the cumulative incidence of atopic dermatitis in healthy infants at risk for dysbiosis at 12 months of age and to identify factors associated with the presence of atopic dermatitis.

Eligibility Criteria:
Inclusion Criteria:

* full-term infant (gestational age ≥ 37 and ≤ 42 weeks) in good health;
* Having at least one risk factor for dysbiosis, including:

  * birth by caesarean section,
  * Antibiotic exposure between birth and inclusion or in utero (mother who received antibiotics) during the last trimester of pregnancy, or per-partum (mother who received antibiotics during childbirth),
  * a family history of allergy confirmed by a doctor in a family member, affecting at least one of the two parents or siblings (asthma, atopic dermatitis, eczema, allergic rhinitis, proven food allergy);
* Aged at most 5 weeks;
* Having a weight in the reference values for gestational age and sex (between the 10th and the 90th percentiles according to the growth curves in force);
* Already consuming an infant formula (with or without associated breast milk), or whose mother wishes to introduce an infant formula at the end of this consultation to switch to mixed breastfeeding or to start weaning;
* Authorization of a parent (or both) or legal representative of the child to collect personal information about their child and family.

Exclusion Criteria:

* Premature infants or low birth weight (\< 2500g);
* Infant allergic to cow's milk protein;
* Infants with severe congenital anomalies that may impact growth (cystic fibrosis, bronchopulmonary dysplasia, tracheomalacia, tracheoesophageal fistula, congenital heart defects ...);
* Infants with chronic disease or severe neonatal pathology, or a pathology predisposing to infections (HIV, hepatitis B or C, autoimmune diabetes, immune deficiency, respiratory distress, sepsis, intraventricular hemorrhage, severe neonatal hepatitis, necrotizing enterocolitis, hypertension persistent pulmonary ...), or renal or hepatic pathology;
* Inability of the parent or legal representative to understand the protocol of the study, or doubts of the physician on the ability or willingness to comply with the protocol.
Employment and Arthritis: Making it Work

The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people with inflammatory arthritis stay employed. The program also includes assessments with 1) an occupational therapist, and 2) a vocational rehabilitation counsellor at the end of the program to help participants identify and obtain necessary changes at work. People from three provinces will be recruited from collaborators' patient and program recipient lists. The study group will receive the program intervention and the control group will receive "usual care" and printed educational material. All participants will be followed for five years. The effectiveness of the program at improving at work productivity and reducing work cessation will be evaluated compared to a control group receiving printed material on employment and arthritis.


Eligibility Criteria:
Inclusion Criteria:

* Between ages 18 and 59 years
* Able to read and write English
* Have inflammatory arthritis confirmed by a rheumatologist (Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis, Other Connective Tissue Diseases and Spondylarthropathy)
* Have access to a computer, a web-cam, a headset and a printer, or willingness to purchase these items
* Are willing to travel to Vancouver, Kelowna, Victoria, Prince Rupert, Prince George, Cranbrook or Kamloops, Calgary, Toronto, Newmarket or Brampton for one visit with an occupational therapist

Exclusion Criteria:

* Individuals who are not working
* Individuals on sick leave, short term or long term work disability
* Students
* People performing unpaid work such as volunteer work or taking care of family
* People planning to retire in the next six years
* Individuals unable to provide informed consent
* Individuals living outside of British Columbia, Alberta, Ontario
Mesenteric Infiltration in Ovarian Cancer

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.


Eligibility Criteria:
Inclusion Criteria:

1. Women with confirmed HGSOC wiht mesenteric involvment
2. Age \> 18 years
3. FIGO STAGE IIIB-IV
4. Primary diagnosis
5. Signed informed consent

Exclusion Criteria:

1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer)
2. Early stage disease (I and II stage)
3. CT scan not available
4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy
Tailored Therapy for Clarithromycin-Resistant H. Pylori

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.


Eligibility Criteria:
Inclusion Criteria:

* peptic ulcer disease
* H. pylori gastritis
* low grade MALT lymphoma

Exclusion Criteria:

* history of gastric cancer surgery
* severe comorbidity (ESRD, LC)
* hypersensitivity to drug
* pregnancy
Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.

The estrogenic properties of glabridin, the major isoflavan in licorice root, were tested in view of the resemblance of its structure and lipophilicity to those of estradiol. The results indicate that glabridin is a phytoestrogen, binding to the human estrogen receptor and stimulating creatine kinase activity in rat uterus, epiphyseal cartilage, diaphyseal bone, aorta, and left ventricle of the heart. The stimulatory effects of 2.5-25 mg/animal glabridin were similar to those of 5 mg/animal estradiol. Chemical modification of glabridin showed that the position of the hydroxyl groups has a significant role in binding to the human estrogen receptor and in proliferation-inducing activity. Glabridin was found to be three to four times more active than 2\*-O-methylglabridin and 4\*-O-methylglabridin, and both derivatives were more active than 2\*,4\*- O-methylglabridin. The effect of increasing concentrations of glabridin on the growth of breast tumor cells was biphasic. Glabridin showed an estrogen receptor-dependent, growth-promoting effect at low concentrations (10 nM-10 mM) and estrogen receptor-independent antiproliferative activity at concentrations of \>15 mM. This is the first study to indicate that isoflavans have estrogen-like activities. Glabridin and its derivatives exhibited varying degrees of estrogen receptor agonism in different tests and demonstrated growth-inhibitory actions on breast cancer cells.

Eligibility Criteria:
Inclusion Criteria:

1. Women between the ages 45-60,
2. Who are post-menopausal (proved by a laboratory test of FSH \> 30 International units),
3. Patients who report having post-menopausal symptoms, who report having, at least 5-7 hot flushes per day, as well as wakeful night episodes and nocturnal sweating (measured by Greenscale or Cooperman Index).

Exclusion Criteria:

1. Female patients who are outside the age boundaries of 45-60,
2. Have FSH \<30
3. Patients who presently have cancer of any kind,
4. Patients that are on any other treatment for relieving post-menopausal symptoms
5. Patients who have contraindication to Licorice.